WNT5A and prostate cancer: The canonical Wnt ligand Wnt3a and the non-canonical ligand Wnt5a were shown to induce BMP-4 and -6 expression in prostate cancer and to stimulate osteoblast differentiation that resulted in osteoblastic lesion formation [128,129].